For Patients and Caregivers
Photo of an OCREVUS vial, 300 mg

The #1 most-prescribed MS DMT in the US1

OCREVUS offers 2X-yearly dosing and a shorter 2-hour infusion option2

DOSING & ADMINISTRATION

How to administer OCREVUS

The first dose of OCREVUS is split between 2 treatments, for a total of 3 treatments in the first year2

Icon of an exclamation point in a circle

Delayed or missed dose2

If a planned infusion of OCREVUS is missed, administer it as soon as possible; do not wait until the next scheduled dose. Reset the dose schedule to administer the next sequential dose 6 months after the missed dose is administered.

  • Perform hepatitis B virus screening2
  • Test for quantitative serum immunoglobulins2
  • Complete necessary vaccinations (4 weeks prior to live or live-attenuated vaccines and, when possible, at least 2 weeks prior for non-live vaccines)2
  • Obtain serum aminotransferases (ALT and AST), alkaline phosphatase, and bilirubin levels2
  • Determine whether there is an active infection. In case of active infection, delay infusion of OCREVUS until the infection resolves2
  • Premedicate with methylprednisolone (or an equivalent corticosteroid) administered intravenously approximately 30 minutes prior to each OCREVUS infusion to reduce the frequency and severity of infusion reactions2
  • Premedicate with an antihistamine (eg, diphenhydramine) approximately 30 to 60 minutes prior to each OCREVUS infusion to further reduce the frequency and severity of infusion reactions. The addition of an antipyretic (eg, acetaminophen) may also be considered2

OCREVUS is administered as an intravenous infusion through a dedicated line2

  • Administer OCREVUS under the close supervision of an experienced healthcare professional with access to appropriate medical support to manage severe reactions such as serious infusion reactions
  • Administer the diluted infusion solution through a dedicated line using an infusion set with a 0.2 or 0.22 micron in-line filter
  • Observe patients for at least 1 hour after the completion of the infusion
  • Inform patients that infusion reactions can occur up to 24 hours after infusion
Photo of a young caucasian woman holding up two fingers

With the OCREVUS dosing schedule, patients only need 2 treatments every 12 months2

*Infusion time may take longer if the infusion is interrupted or slowed.2
†For all doses, post-infusion monitoring with access to appropriate medical support to manage severe infusion reactions for at least 1 hour after infusion is recommended.2

INFUSION RATES & MODIFICATIONS

Rate modifications in the event of infusion reactions

Modify the infusion rate in response to the severity of the reaction. For infusion reactions that are not life-threatening, the change in infusion rate will increase the duration of the infusion but not the total dose2

MILD/MODERATE
Reduce the infusion rate to half the rate of when the reaction began and maintain the reduced rate for at least 30 minutes. If tolerated, increase the infusion rate according to the initial infusion schedule.
SEVERE
Interrupt the infusion immediately and provide supportive treatment. Only restart the infusion after all symptoms have been resolved, at half the infusion rate of when the reaction began.
LIFE-THREATENING OR DISABLING
Immediately stop the infusion and provide appropriate supportive treatment. Permanently discontinue OCREVUS in these patients.

Infusion reactions in clinical studies

No life-threatening, fatal, or serious IRs occurred with OCREVUS in the ENSEMBLE PLUS study.2

  • 2-hour infusion is available for patients who have not experienced serious infusion reactions with any previous OCREVUS infusion2
  • Overall, in all randomized doses, 27.1% of the patients in the 2-hour infusion group and 25.0% of the patients in the 3.5-hour infusion group reported mild or moderate infusion reactions; 2 infusion reactions were severe in intensity, with 1 severe infusion reaction (0.3%) reported in 1 patient in each group in this substudy2

The proportion of patients with IRs were similar between the 2 infusion protocols2

24.4%

2-hour infusion

23.3%

3.5- to 4-hour infusion

3.5- to 4-hour infusion of OCREVUS: 99.7% of infusions did not result in serious IRs.2

  • IRs were highest with the first infusion. Of the IRs that occurred, most were mild to moderate in severity2
  • 0.3% of OCREVUS-treated patients with MS experienced IRs that were serious, some requiring hospitalization2

Infusion rate tables

Initial dose Subsequent doses

Initial dose (600 mg) administered as 2 infusions2

Infusion 1

Day 1
300 mg in 250 mL

2.5 hour infusion: Start at a rate of 30 mL/hr. Thereafter, increase the rate by 30 mL/hr every 30 minutes to a maximum of 180 mL/hr. Each infusion will last 2.5 hours or longer.*

Infusion 2

Day 15
300 mg in 250 mL

*Infusion time may take longer if the infusion is interrupted or slowed.2

Subsequent doses (600 mg) once every 6 months*

Single infusion

600 mg in 500 mL

3.5- to 4-hour infusion: Start at a rate of 40 mL/hr. Thereafter, increase the rate by 40 mL/hr every 30 minutes to a maximum of 200 mL/hr. Each infusion will last 3.5 hours or longer.†

2-hour shorter infusion

600 mg in 500 mL

Start at a rate of 100 mL/hr. Thereafter, increase the rate as shown below to a maximum of 300 mL/hr. Each infusion will last 2 hours or longer.†

Available for patients without prior serious infusion reactions with any OCREVUS (ocrelizumab) infusion.

*Administer the first subsequent dose 6 months after the first infusion of the initial dose.
†Infusion time may be longer if the infusion is interrupted or slowed.

Solutions of OCREVUS for intravenous infusion are prepared by dilution of the drug product into an infusion bag containing 0.9% sodium chloride injection to a final drug concentration of approximately 1.2 mg/mL.2

ADHERENCE & PERSISTENCE

Real-world analysis of patients treated with OCREVUS and KESIMPTA with 2 years of follow-up

Study design for OCREVUS real-world analysis among patients with 2 years of follow-up4

OCREVUS (ocrelizumab) and Kesimpta® (ofatumumab) were studied using real-world US commercial, Medicare, and Medicaid claims data from IQVIA PharMetrics® Plus

  • Adherence and persistence over a 2-year period were evaluated in the IQVIA PharMetrics Plus database*
  • Inclusion criteria included: patients ≥18 years of age with a diagnosis of MS who initiated OCREVUS or Kesimpta using a confirmed† loading dose between August 20, 2020, and December 31, 2021; at least ≥12 months of continuous health plan enrollment prior to treatment initiation (index date)‡ with 24 months of follow-up data
  • Exclusion criteria included: patients initiating multiple DMTs on index; patients with any claims of index DMT in the prior 12 months
  • In this sensitivity analysis, adjustments for overlapping days' supply were not made for either OCREVUS or Kesimpta
  • Adherence was calculated based on proportion of days covered (PDC), with ≥80% considered adherent to the DMT initiated
    • PDC = number of days of supply or administration divided by 730 days
  • Persistence measured the duration of time from initiation to discontinuation of therapy
    • The date of discontinuation was defined as the earliest of DMT switch date or the end supply date of last index DMT fill before treatment gap

Limitations for OCREVUS real-world analysis among patients with 2 years of follow-up4

  • Analyses using administrative pharmacy and medical claims data are dependent on the accuracy and specificity of information provided
  • Adherence and persistence were calculated based on the administration schedule recommended in each product’s Prescribing Information and days’ supply as shown in claims for Kesimpta; instances where prescribing patterns differ from the FDA-approved administration schedules, adherence and persistence may be misclassified
  • Differences in dosing and pharmacodynamics should be considered when making direct comparisons between DMTs
    • Kesimpta is a monthly subcutaneous injection; please refer to the PI for Kesimpta for additional information5
  • Claims data have inherent limitations:
    • Unable to ascertain if patients on self-administered medications, including Kesimpta, took DMT as prescribed
    • Limited clinical information available may impact interpretation of results (eg, MS subtype, line of therapy). ICD-10 codes do not identify patients by MS subtypes
    • Lack of data on reason for discontinuation
  • Data may not be generalized to all patients, including those without insurance, and may be limited to the study population of commercially insured patients in the US
  • Real-world adherence and persistence rates should not be considered as a comparison of safety and efficacy

Real-world analysis§ of OCREVUS and Kesimpta-treated patients with 2 years of follow-up4

Adherence

Among patients with 2 years of follow-up

27% relative risk reduction

of nonadherence for OCREVUS vs KESIMPTA patients

RR=0.73 (95% CI: 0.60-0.89)

Persistence

Among patients with 2 years of follow-up

8% relative risk reduction

of nonpersistence for OCREVUS vs KESIMPTA patients

RR=0.82 (95% CI: 0.68-0.98)

OCREVUS clinical trial completion

In the OCREVUS RMS clinical trials, the percentage of patients who completed the clinical trials at year 2 were:

*IQVIA PharMetrics Plus Q2 2024 Data Delivery (fully adjudicated medical and pharmacy claims data through 2023 Q4).4
†OCREVUS loading dose definition: a gap of 13 to 21 days between 1st and 2nd OCREVUS claim; Kesimpta loading dose definition: quantity equal to 1.2 and days’ supply equal to either 28 or 30 days on 1st Kesimpta claim.4
‡Index date=OCREVUS or Kesimpta initiation date.
§Results based on a sensitivity analysis from a retrospective cohort study using fully adjudicated medical and pharmacy claims from August 2019 through December 2023 extracted from the IQVIA PharMetrics Plus database.4

PREPARATION & STORAGE

Preparing & storing OCREVUS2

  • OCREVUS must be prepared by a healthcare professional using aseptic technique
  • Visually inspect for particulate matter and discoloration prior to administration. Do not use the solution if discolored or if the solution contains discrete foreign particulate matter. Do not shake
  • Withdraw intended dose and further dilute into an infusion bag containing 0.9% sodium chloride injection to a final drug concentration of approximately 1.2 mg/mL
    • Withdraw 10 mL (300 mg) of OCREVUS and inject into 250 mL
    • Withdraw 20 mL (600 mg) of OCREVUS and inject into 500 mL
  • Do not use other diluents to dilute OCREVUS since their use has not been tested. The product contains no preservative and is intended for single use only
  • Prior to the start of the intravenous infusion, the contents of the infusion bag should be at room temperature
  • Use the prepared solution immediately. If not used immediately, store up to 24 hours in the refrigerator at 2°C to 8°C (36°F to 46°F) and 8 hours at room temperature up to 25°C (77°F), which includes infusion time. In the event an intravenous infusion cannot be completed the same day, discard the remaining solution
  • No incompatibilities between OCREVUS and polyvinyl chloride or polyolefin bags and intravenous administration sets have been observed

ALT=alanine aminotransferase; AST=aspartate aminotransferase; DMT=disease-modifying treatment; FDA=Food and Drug Administration; IR=infusion reaction; ICD-10=International Classification of Diseases, Tenth Revision; IV=intravenous; MS=multiple sclerosis; PI=Prescribing Information; RR=relative risk.

NEXT: OCREVUS [IV] Efficacy

 

Important Safety Information & Indications

Indications

OCREVUS and OCREVUS ZUNOVO are indicated for the treatment of:

  • Relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults
  • Primary progressive MS, in adults.
Contraindications

Treatment with ocrelizumab is contraindicated in patients with active hepatitis B virus infection and in patients with a history of life-threatening administration reactions to ocrelizumab. OCREVUS ZUNOVO is also contraindicated in patients with a history of hypersensitivity to ocrelizumab, hyaluronidase, or any component of OCREVUS ZUNOVO.

Warnings and Precautions
Injection Reactions (OCREVUS ZUNOVO) OR Infusion Reactions (OCREVUS)

OCREVUS ZUNOVO can cause injection reactions, which can be local or systemic. Common symptoms of local injection reactions reported by patients treated with OCREVUS ZUNOVO in multiple sclerosis (MS) clinical trials included erythema, pain, swelling, and pruritus. Common symptoms of systemic injection reactions reported by patients included headache and nausea. In an open-label, active-controlled trial, injection reactions were more frequently reported with the first injection; 49% of patients experienced an injection reaction with the first injection.

In OCREVUS MS clinical trials, the incidence of infusion reactions in patients [who received methylprednisolone (or an equivalent steroid) and possibly other pre-medication to reduce the risk of infusion reactions prior to infusion] was 34% to 40%, with the highest incidence with the first infusion. There were no fatal infusion reactions, but 0.3% of intravenous ocrelizumab-treated MS patients experienced infusion reactions that were serious, some requiring hospitalization. Symptoms of infusion reactions can include pruritus, rash, urticaria, erythema, bronchospasm, throat irritation, oropharyngeal pain, dyspnea, pharyngeal or laryngeal edema, flushing, hypotension, pyrexia, fatigue, headache, dizziness, nausea, tachycardia, and anaphylaxis.

Monitor OCREVUS ZUNOVO patients during and after injections. Observe patients treated with OCREVUS for infusion reactions during the infusion and for at least one hour after completion of the infusion. Inform patients that administration reactions can occur during or within 24 hours of treatment.

Reducing the Risk and Managing Injection or Infusion Reactions

For OCREVUS ZUNOVO, administer oral pre-medication (e.g., dexamethasone or an equivalent corticosteroid, and an antihistamine) at least 30 minutes prior to each OCREVUS ZUNOVO injection to reduce the risk of injection reactions. The addition of an antipyretic (e.g., acetaminophen) may also be considered.

For OCREVUS, administer pre-medication (e.g., methylprednisolone or an equivalent corticosteroid, and an antihistamine) to reduce the frequency and severity of infusion reactions. The addition of an antipyretic (e.g., acetaminophen) may also be considered.

Management recommendations depend on the type and severity of the reaction. For life-threatening reactions, immediately and permanently stop OCREVUS ZUNOVO or OCREVUS and administer appropriate supportive treatment. For less severe OCREVUS ZUNOVO injection reactions, the injection should be interrupted immediately, and the patient should receive symptomatic treatment. The injection should be completed at the healthcare provider’s discretion and only after all symptoms have resolved. For less severe OCREVUS infusion reactions, management may involve temporarily stopping the infusion, reducing the infusion rate, and/or administering symptomatic treatment.

Infections

Serious, including life-threatening or fatal, bacterial, viral, parasitic and fungal infections have been reported in patients receiving ocrelizumab. An increased risk of infections (including serious and fatal bacterial, fungal, and new or reactivated viral infections) has been observed in patients during and following completion of treatment with anti-CD20 B-cell depleting therapies.

A higher proportion of OCREVUS-treated patients experienced infections compared to patients taking REBIF or placebo. In RMS trials, 58% of OCREVUS-treated patients experienced one or more infections compared to 52% of REBIF-treated patients. In the PPMS trial, 70% of OCREVUS-treated patients experienced one or more infections compared to 68% of patients on placebo. OCREVUS was not associated with an increased risk of serious infections in MS patients in controlled trials.

Ocrelizumab increases the risk for upper respiratory tract infections, lower respiratory tract infections, skin infections, and herpes-related infections. Delay administration of ocrelizumab in patients with an active infection until the infection has resolved.

Respiratory Tract Infections

A higher proportion of OCREVUS-treated patients experienced respiratory tract infections compared to patients taking REBIF or placebo. In RMS trials, 40% of OCREVUS-treated patients experienced upper respiratory tract infections compared to 33% of REBIF-treated patients, and 8% of OCREVUS-treated patients experienced lower respiratory tract infections compared to 5% of REBIF-treated patients. In the PPMS trial, 49% of OCREVUS-treated patients experienced upper respiratory tract infections compared to 43% of patients on placebo, and 10% of OCREVUS-treated patients experienced lower respiratory tract infections compared to 9% of patients on placebo. The infections were predominantly mild to moderate and consisted mostly of upper respiratory tract infections and bronchitis.

Herpes

In active-controlled (RMS) clinical trials, herpes infections were reported more frequently in OCREVUS-treated patients than in REBIF-treated patients, including herpes zoster (2.1% vs. 1.0%), herpes simplex (0.7% vs. 0.1%), oral herpes (3.0% vs. 2.2%), genital herpes (0.1% vs. 0%), and herpes virus infection (0.1% vs. 0%). Infections were predominantly mild to moderate in severity. In the placebo-controlled (PPMS) clinical trial, oral herpes was reported more frequently in the OCREVUS-treated patients than in the patients on placebo (2.7% vs. 0.8%).

Serious cases of infections caused by herpes simplex virus and varicella zoster virus, including central nervous system infections (encephalitis and meningitis), intraocular infections, and disseminated skin and soft tissue infections, have been reported in the postmarketing setting in multiple sclerosis patients receiving ocrelizumab. Serious herpes virus infections may occur at any time during treatment with ocrelizumab. Some cases were life-threatening.

If serious herpes infections occur, treatment with ocrelizumab should be discontinued or withheld until the infection has resolved, and appropriate treatment should be administered.

Hepatitis B Virus Reactivation

Hepatitis B virus (HBV) reactivation has been reported in MS patients treated with ocrelizumab in the postmarketing setting. Fulminant hepatitis, hepatic failure, and death caused by HBV reactivation have occurred in patients treated with anti-CD20 antibodies. Perform HBV screening in all patients before initiation of treatment with ocrelizumab. Do not administer ocrelizumab to patients with active HBV confirmed by positive results for HBsAg and anti-HB tests. For patients who are negative for surface antigen [HBsAg] and positive for HB core antibody [HBcAb+] or are carriers of HBV [HBsAg+], consult liver disease experts before starting and during treatment.

Possible Increased Risk of Immunosuppressant Effects With Other Immunosuppressants

When initiating treatment with ocrelizumab after an immunosuppressive therapy or initiating an immunosuppressive therapy after ocrelizumab-containing products, consider the potential for increased immunosuppressive effect. Treatment with ocrelizumab has not been studied in combination with other MS therapies.

Vaccinations

Administer all immunizations according to immunization guidelines at least 4 weeks prior to initiation of ocrelizumab treatment for live or live-attenuated vaccines and, whenever possible, at least 2 weeks prior to initiation of ocrelizumab treatment for non-live vaccines. Ocrelizumab may interfere with the effectiveness of non-live vaccines. The safety of immunization with live or live-attenuated vaccines following treatment with ocrelizumab has not been studied, and vaccination with live-attenuated or live vaccines is not recommended during treatment and until B-cell repletion.

Vaccination of Infants Born to Mothers Treated With Ocrelizumab Products During Pregnancy

In infants of mothers exposed to ocrelizumab during pregnancy, do not administer live or live-attenuated vaccines before confirming the recovery of B-cell counts as measured by CD19+ B-cells. Depletion of B-cells in these infants may increase the risks from live or live-attenuated vaccines.

You may administer non-live vaccines, as indicated, prior to recovery from B-cell depletion, but you should consider assessing vaccine immune responses, including consultation with a qualified specialist, to assess whether a protective immune response was mounted.

Progressive Multifocal Leukoencephalopathy

Cases of progressive multifocal leukoencephalopathy (PML) have been reported in patients with MS treated with ocrelizumab in the postmarketing setting. PML is an opportunistic viral infection of the brain caused by the JC virus (JCV) that typically occurs only in patients who are immunocompromised, and that usually leads to death or severe disability. PML has occurred in ocrelizumab-treated patients who had not been treated previously with natalizumab, (which has a known association with PML), were not taking any immunosuppressive or immunomodulatory medications associated with risk of PML prior to or concomitantly with ocrelizumab and did not have any known ongoing systemic medical conditions resulting in compromised immune system function.

JCV infection resulting in PML has also been observed in patients treated with other anti-CD20 antibodies and other MS therapies.

At the first sign or symptom suggestive of PML, withhold treatment with ocrelizumab-containing products and perform an appropriate diagnostic evaluation. Typical symptoms associated with PML are diverse, progress over days to weeks, and include progressive weakness on one side of the body or clumsiness of limbs, disturbance of vision, and changes in thinking, memory, and orientation leading to confusion and personality changes. 

Magnetic resonance imaging (MRI) findings may be apparent before clinical signs or symptoms of PML. Monitoring with MRI for signs consistent with PML may be useful, and any suspicious findings should lead to further investigation to allow for an early diagnosis of PML, if present. If PML is confirmed, treatment with ocrelizumab should be discontinued.

Reduction in Immunoglobulins

As expected with any B-cell depleting therapy, decreased immunoglobulin levels are observed with ocrelizumab treatment. The pooled data of OCREVUS clinical studies (RMS and PPMS) and their open-label extensions (up to approximately 7 years of exposure) have shown an association between decreased levels of immunoglobulin G (IgG<LLN) and increased rates of serious infections. Monitor the levels of quantitative serum immunoglobulins during treatment with ocrelizumab and after discontinuation of treatment, until B-cell repletion, and especially in the setting of recurrent serious infections. Consider discontinuing treatment with ocrelizumab in patients with serious opportunistic or recurrent serious infections, and if prolonged hypogammaglobulinemia requires treatment with intravenous immunoglobulins.

Malignancies

An increased risk of malignancy with ocrelizumab may exist. In controlled trials, malignancies, including breast cancer, occurred more frequently in OCREVUS-treated patients. Breast cancer occurred in 6 of 781 females treated with OCREVUS and none of 668 females treated with REBIF or placebo. Patients should follow standard breast cancer screening guidelines.

Immune-Mediated Colitis

Immune-mediated colitis, which can present as a severe and acute-onset form of colitis, has been reported in patients receiving ocrelizumab in the postmarketing setting. Some cases of colitis were serious, requiring hospitalization, with a few patients requiring surgical intervention. Systemic corticosteroids were required in many of these patients. The time from treatment initiation to onset of symptoms in these cases ranged from a few weeks to years. Monitor patients for immune-mediated colitis during ocrelizumab treatment and evaluate promptly if signs and symptoms that may indicate immune-mediated colitis, such as new or persistent diarrhea or other gastrointestinal signs and symptoms, occur.

Liver Injury

Clinically significant liver injury, without findings of viral hepatitis, has been reported in the postmarketing setting in patients treated with anti-CD20 B-cell depleting therapies approved for the treatment of MS, including ocrelizumab. Signs of liver injury, including markedly elevated serum hepatic enzymes with elevated total bilirubin, have occurred from weeks to months after administration.

Patients treated with ocrelizumab found to have an alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater than 3x the upper limit of normal (ULN) with serum total bilirubin greater than 2x ULN are potentially at risk for severe drug-induced liver injury.

Obtain liver function tests prior to initiating treatment with ocrelizumab, and monitor for signs and symptoms of any hepatic injury during treatment. Measure serum aminotransferases, alkaline phosphatase, and bilirubin levels promptly in patients who report symptoms that may indicate liver injury, including new or worsening fatigue, anorexia, nausea, vomiting, right upper abdominal discomfort, dark urine, or jaundice. If liver injury is present and an alternative etiology is not identified, discontinue ocrelizumab.

Use in Specific Populations
Pregnancy

There are no adequate data on the developmental risk associated with use of ocrelizumab in pregnant women. There are no data on B-cell levels in human neonates following maternal exposure to ocrelizumab-containing products. However, transient peripheral B-cell depletion and lymphocytopenia have been reported in infants born to mothers exposed to other anti-CD20 antibodies during pregnancy. Ocrelizumab is a humanized monoclonal antibody of an immunoglobulin G1 subtype and immunoglobulins are known to cross the placental barrier.

Lactation

There are no data on the presence of ocrelizumab or hyaluronidase in human milk, the effects on the breastfed infant, or the effects of the drug on milk production. Ocrelizumab was excreted in the milk of ocrelizumab-treated monkeys. Human IgG is excreted in human milk, and the potential for absorption of ocrelizumab to lead to B-cell depletion in the infant is unknown. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for ocrelizumab and any potential adverse effects on the breastfed infant from ocrelizumab or from the underlying maternal condition.

Females and Males of Reproductive Potential

Women of childbearing potential should use effective contraception while receiving ocrelizumab and for 6 months after the last dose of ocrelizumab. Instruct patients that if they are pregnant or plan to become pregnant while taking OCREVUS or OCREVUS ZUNOVO, they should inform their healthcare provider.

Most Common Adverse Reactions

In patients treated with OCREVUS:

  • RMS: The most common adverse reactions (≥10% and >REBIF): upper respiratory tract infections and infusion reactions
  • PPMS: The most common adverse reactions (≥10% and >placebo): upper respiratory tract infections, infusion reactions, skin infections, and lower respiratory tract infections

The most common adverse reaction observed with OCREVUS ZUNOVO in patients with RMS and PPMS was injection reactions (incidence of 49%).

You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835-2555.

Please see additional Important Safety Information throughout and click here for full OCREVUS Prescribing Information and Medication Guide. For OCREVUS ZUNOVO, click here for full Prescribing Information and Medication Guide.

    • Data on file. Genentech, Inc. September 2023.

      Data on file. Genentech, Inc. September 2023.

    • OCREVUS [prescribing information]. South San Francisco, CA: Genentech, Inc. 2025.

      OCREVUS [prescribing information]. South San Francisco, CA: Genentech, Inc. 2025.

    • Mayer L, Kappos L, Racke M, et al. Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies. Mult Scler Relat Disord. 2019;30:236-243. doi:10.1016/j.msard.2019.01.044

      Mayer L, Kappos L, Racke M, et al. Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies. Mult Scler Relat Disord. 2019;30:236-243. doi:10.1016/j.msard.2019.01.044

    • Pineda ED, Miller A, Patel A, Pardo G. Real-world adherence and persistence to ocrelizumab vs ofatumumab among people with multiple sclerosis over 24 months. Poster presented at: ACTRIMS Forum 2025; February 27–March 1, 2025; West Palm Beach, Florida, USA, and virtual. Poster P406.

      Pineda ED, Miller A, Patel A, Pardo G. Real-world adherence and persistence to ocrelizumab vs ofatumumab among people with multiple sclerosis over 24 months. Poster presented at: ACTRIMS Forum 2025; February 27–March 1, 2025; West Palm Beach, Florida, USA, and virtual. Poster P406.

    • Kesimpta. Prescribing information. Novartis Pharmaceuticals Corp.

      Kesimpta. Prescribing information. Novartis Pharmaceuticals Corp.